Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
In8Bio, Inc. (INAB) is a clinical-stage biopharmaceutical leader developing gamma-delta T cell immunotherapies for cancer treatment. This page provides investors and researchers with essential updates on clinical trials, regulatory developments, and strategic partnerships driving innovation in cellular therapies.
Access real-time announcements about the company's DeltEx platform advancements, chemotherapy-resistant cell therapies, and progress across solid tumor and hematologic malignancy programs. Our curated news collection includes earnings reports, trial data publications, and collaborative research milestones.
Key updates cover FDA designations, preclinical study results, and technology licensing agreements. All content is verified for accuracy and relevance to support informed decision-making in the oncology investment space.
Bookmark this page for streamlined access to In8Bio's latest scientific achievements and corporate developments. Check regularly for authoritative updates on one of biotech's most promising cancer immunotherapy innovators.
IN8bio (NASDAQ: INAB) has announced it will present new preclinical data on its novel gamma-delta (γδ) T cell engager platform at the AACR Annual Meeting 2025 in Chicago. The presentation will showcase the company's innovative approach to cancer immunotherapy, combining gamma-delta T cells' innate tumor-recognition capabilities with bispecific engagers.
The research focuses on overcoming limitations of current CD-3 based engager therapies by leveraging unique properties of gamma-delta T cells, including tissue residence, phagocytosis, and low IL-6 secretion. Early findings in AML and B-ALL demonstrate potential for targeted immune responses against multiple antigens.
The poster presentation titled 'A novel gamma-delta T cell engager platform for cancer immunotherapy' (Abstract #7321) will be presented on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CT.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, has announced its participation in the 11th Annual Immuno-Oncology 360° Conference 2025 in Boston, MA from March 24-26, 2025.
William Ho, CEO and co-founder, will serve as Co-Chair for Day 2 on March 25, leading key sessions including:
- Welcome remarks and discussion on 'Tackling the Tough Questions in IO for Autoimmunity Disease' at 8:15 AM EDT
- Chairing the 'State of the IO Market, Investments and Deals Plenary'
- Presentation on 'Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager' at 4:35 PM EDT
The presentations will highlight IN8bio's recently announced INB-619 T cell engager program for oncology and autoimmune diseases, focusing on the potential of gamma-delta T cell engagers in addressing autoimmunity.
IN8bio (INAB) reported its Q4 and full-year 2024 financial results, highlighting significant clinical progress in its gamma-delta T cell therapies. The company's INB-100 program demonstrated 100% long-term durable response rates in high-risk AML patients as of January 2025. The Phase 1 INB-200 trial for glioblastoma showed promising durability, with five patients remaining alive and one patient progression-free for 40.5 months.
Financial highlights include R&D expenses of $17.2M for 2024 (vs $16.8M in 2023), G&A expenses of $12.6M (vs $13.5M), and a net loss of $30.7M ($0.57 per share). The company ended 2024 with cash of $11.1M, raised additional $4.1M in February 2025, and expects runway into March 2026.
IN8bio introduced its INB-600 platform featuring a novel gamma-delta T Cell engager targeting CD19 for oncology and autoimmune diseases. The company implemented cost-saving measures and paused the Phase 2 INB-400 glioblastoma program to optimize resource allocation.
IN8bio (NASDAQ: INAB) has unveiled INB-600, a novel gamma-delta (γδ) T cell-based TCE platform designed to overcome the limitations of current γδ TCEs. The platform's first candidate, INB-619, targets CD19 for applications in leukemias, lymphomas, and autoimmune diseases.
Key preclinical findings for INB-619 include:
- Rapid B-cell depletion with γδ T cells expanding up to 450-fold
- Simultaneous activation of both Vδ1+ and Vδ2+ T cell subsets
- Lower IL-6 secretion, potentially reducing risks of cytokine release syndrome (CRS) and neurotoxicity (ICANs)
The platform represents the first known approach capable of sustained γδ T cell expansion, offering potentially greater safety and tolerability compared to current CAR-T and TCE approaches. IN8bio plans to evaluate INB-619 in preclinical studies and seek partners for future IND-enabling trials.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. William Ho, CEO and co-founder, will deliver a presentation on Monday, March 3, 2025, at 10:30 a.m. ET.
Interested parties can access both the live webcast and replay of the presentation through the 'Events and Presentations' section within the News & Presentations area on IN8bio's investor relations website at https://investors.in8bio.com.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company's CEO and co-founder, William Ho, will deliver a presentation on Tuesday, February 25, 2025, at 11:00 a.m. ET.
The presentation will be accessible through a live webcast, with a replay option available afterward. Interested parties can access the webcast through the provided link or find it in the 'Events and Presentations' section under News & Presentations on IN8bio's investor relations website.
IN8bio (Nasdaq: INAB) presented Phase 1 data for INB-100, its allogeneic gamma-delta T cell therapy, showing significant promise in treating high-risk acute myeloid leukemia (AML). The data revealed zero relapses in AML patients with a median follow-up of 20.1 months. The therapy demonstrated impressive outcomes with a 90.9% progression-free survival rate and 100% overall survival at one year.
The treatment showed a favorable safety profile with no cytokine release syndrome, neurotoxicity, or dose-limiting toxicities. Evidence of in vivo expansion and long-term persistence of gamma-delta T cells was observed. With approximately 20,000 new AML cases and 11,500 deaths annually in the U.S., and post-HSCT relapse occurring in up to 50% of patients, INB-100 addresses a significant unmet medical need.
The company plans to complete enrollment of the expansion cohort in 2025, with FDA confirming relapse-free survival as an acceptable primary endpoint for a future pivotal trial.
IN8bio (NASDAQ: INAB) reported updated results from its Phase 1 trial of INB-100, an allogeneic gamma-delta T cell therapy for acute myeloid leukemia (AML) patients. 100% of AML patients remain in complete remission with a median follow-up of 20.1 months, with the original cohort reaching a median CR of 23.3 months. Several patients have maintained remission for over three years.
The trial demonstrated significantly higher survival rates compared to historical data, with 90.9% progression-free survival (PFS) and 100% overall survival (OS) at one year across all patients. For AML patients specifically, both PFS and OS were 100% at one year. The therapy shows particular promise in older, high-risk patients receiving reduced intensity conditioning, with a median age of 68. Notably, the treatment has been well-tolerated with no cytokine release syndrome or neurotoxicity, and manageable graft-versus-host disease.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, has announced its participation in Biotech Showcase 2025 in San Francisco. CEO and co-founder William Ho will participate in two key events:
1. A panel discussion on 'The Battle Against Cancer: The Armamentarium Keeps Expanding' on Monday, January 13, 2025, at 8:00 AM PT
2. A corporate presentation on Tuesday, January 14, 2025, at 2:00 PM PT
Both events will take place at the Hilton San Francisco Union Square Hotel. The company's management will also be available for investor meetings from January 13-16, 2025, during the 43rd Annual J.P. Morgan Health Care Conference. A live webcast of the presentation will be available, and interested parties can register for the event through the provided links.
IN8bio reported updated data from its Phase 1 trial of INB-100, an allogeneic gamma-delta T cell therapy for leukemia patients. Key highlights include:
- All patients (n=10) maintained complete remission (CR) with no relapses after a median follow-up of 19.7 months
- Three high-risk cytogenetic AML patients remained in CR for over three years without maintenance therapy
- The therapy showed durable in vivo expansion and persistence of allogeneic gamma-delta T cells for 365 days post-administration
- Safety profile remained favorable with no cytokine release syndrome or neurotoxicity
The trial enrolled patients with median age 68 years, mostly diagnosed with AML in CR1. Based on positive results, the trial has been expanded with additional patient enrollment at Dose Level 2, with new data expected in H1 2025.
